dr now glp 1 drops GLP-1 For years, conventional wisdom held
Description
Here, NYUs Dr
An observational cohort study involving 47,719 adults (753 treated with tirzepatide and 46,966 on GLP-1RA) reinforced the cardio-renal benefits of tirzepatide
[15] However, subsequent analysis revealed important context: the increased risk was predominantly observed in patients with pre-existing diabetic retinopathy and those who experienced rapid improvements in glycaemic control
The pathogenic mechanism of obesity is the chronic macrophage production of pro-inflammatory cytokines leading to abnormal cell proliferation [20]
Tirzepatide produced weight loss at 72 weeks in the range of bariatric surgery, so a case can be made that this will be a cost-effective therapy
The GLP-1 agonist market is expected to grow from $70 billion in 2025 to $201 billion in 2030 1 according to Grandview Research
